Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar Anti–tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-world Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Metho
About 80% of individuals initiating infliximab or adalimumab for IBD were still on these drugs at 12 months. Benefits (including less corticosteroid use, abdominal pain, bowel urgency, and improved QoL) were seen in individuals initiating both biosimilar and bio-originators.
Authors
- Cristiano Soares de Moura (ORCID: https://orcid.org/0000-0002-2109-0709)
- Waqqas Afif (ORCID: https://orcid.org/0000-0001-6869-0982)
- Yvette Leung (ORCID: https://orcid.org/0000-0002-8699-4370)
- Neeraj Narula (ORCID: https://orcid.org/0000-0002-1536-8436)
- Petros Zezos (ORCID: https://orcid.org/0000-0001-8877-7583)
- Marina Gabriela Birck (ORCID: https://orcid.org/0000-0003-3003-1839)
- Sasha Bernatsky (ORCID: https://orcid.org/0000-0002-9515-2802)
- Banke Oketola (ORCID: https://orcid.org/0000-0003-3201-4522)
- Harminder Singh (ORCID: https://orcid.org/0000-0002-9354-2356)
- Luck Lukusa
- Autumn Neville
Institutions
- University of British Columbia (CA)
- McGill University Health Centre (CA)
- University of Manitoba (CA)
- McGill University (CA)
- Hamilton Health Sciences (CA)
- NOSM University (CA)
Publication Details
- Journal
- Gastro Hep Advances
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.gastha.2025.100821
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00